Cure My Disease

Don't miss your cure!

 Log in / Sign up

AI trained to spot hidden cancer spread in throat cancer scans

NCT ID NCT05565313

Diagnosis Sponsor: Maastricht Radiation Oncology Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Oct 09, 2026 · Last updated Oct 09, 2026

Summary

Researchers are developing an artificial intelligence model that reads CT and MRI scans to predict whether oropharyngeal cancer has spread outside lymph nodes, a condition called extranodal extension. The study uses scans from 900 patients treated between 2008 and 2019 with radiation or chemoradiation. The goal is to see if the AI can match radiologists at identifying this spread, which could help guide treatment decisions.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
an artificial intelligence model that reads medical scans
What this could lead to
If the model works, doctors could use routine scans to spot cancer spread outside lymph nodes more reliably, helping them choose the right treatment intensity.
What could go wrong
The model learns from scans taken between 2008 and 2019 at specific centers, so it may not perform as well on different patient groups or newer imaging equipment. It also needs validation before it can be used in clinics.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

900 people

The number who actually took part.

Started

Mar 2022

Finished

Aug 2026

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

Inclusion criteria: * Non-metastatic (M0) node-positive HPV+ and HPV- (human papilloma virus) oropharyngeal carcinoma * Treated between 2008 to 2019 * Curative intent * Radiation only or concurrent chemoradiation * Modern treatment modality: IMRT / VMAT (Intensity Modulated RadioTherapy / Volumetric-Modulated Arc Therapy) * diagnostic/staging image scanning protocols available (contrast-enhanced CT with 2-3 mm slice thickness and/or MR (magnetic resonance) with 3 mm slice thickness) Exclusion criteria: * removal of lymph node (LN) (excisional biopsy or neck dissection \[ND\]) prior to staging CT/MR scan * no available imaging within 2 months prior to radiotherapy (RT)"

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion criteria: * Non-metastatic (M0) node-positive HPV+ and HPV- oropharyngeal carcinoma * Treated between 2008 to 2019 * Curative intent * Radiation only or concurrent chemoradiation * Modern treatment modality: IMRT / VMAT * diagnostic/staging image scanning protocols available (contrast-enhanced CT with 2-3 mm slice thickness and/or MR with 3 mm slice thickness) Exclusion criteria: * removal of lymph node (LN) (excisional biopsy or neck dissection \[ND\]) prior to staging CT/MR scan * no available imaging within 2 months prior to radiotherapy (RT)"

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Head and neck carcinoma are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

head and neck carcinoma oropharynx squamous cell carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Head and neck carcinoma

Contacts and locations

Locations

  • Harvard Medical School and clinical faculty at Dana-Farber Cancer Institute/Brigham and Women's Hospital

    Boston, Massachusetts, 02115, United States

  • Maastro

    Maastricht, Limburg, 6229 ET, Netherlands

  • Princess Margaret Cancer Centre

    Toronto, Ontario, M5G 2M9, Canada

More trials for these conditions

Other studies related to the condition(s) this trial covers.